Results 301 to 310 of about 38,942 (318)

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Ophthalmology, 2012
Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald   +2 more
exaly  

Safety in Aflibercept versus Ranibizumab

Ophthalmology, 2014
openaire   +3 more sources

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Ophthalmology, 2010
Michael J Elman, Roy W Beck, Jennifer K Sun   +2 more
exaly  

Ranibizumab for Macular Edema following Central Retinal Vein Occlusion

Ophthalmology, 2010
Peter A Campochiaro, Rishi P Singh
exaly  

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

American Journal of Ophthalmology, 2009
Philip J Rosenfeld, Harry W Flynn
exaly  

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

New England Journal of Medicine, 2015
Lee M Jampol, Michael J Elman, Jennifer K Sun   +2 more
exaly  

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Ophthalmology, 2015
Michael J Elman, Lee M Jampol
exaly  

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

American Journal of Ophthalmology, 2007
Philip J Rosenfeld, Harry W Flynn
exaly  

Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study

Ophthalmology, 2011
Peter A Campochiaro
exaly  

Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

Ophthalmology, 2013
Allen C Ho
exaly